Cullinan Therapeutics, Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $0 | $18.9M | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $91.9M | $57.8M | $43.2M |
| SG&A Expense | $40.2M | $29.1M | $17.1M |
| Operating Income | $144.6M | $-68.0M | $-60.3M |
| Operating Margin | — | -358.7% | — |
| Interest Expense | — | — | — |
| Pretax Income | $151.3M | $-67.5M | — |
| Income Tax Expense | $42.1M | $0 | — |
| Net Income | $111.2M | $-65.6M | $-51.8M |
| Net Margin | — | -346.1% | — |
| EPS (Basic) | $2.46 | $-1.52 | $-2.60 |
| EPS (Diluted) | $2.38 | $-1.52 | $-2.60 |
| Shares Outstanding (Basic) | 45.2M | 43.1M | 29.8M |
| Shares Outstanding (Diluted) | 46.6M | 43.1M | 29.8M |
| Dividends Per Share | — | — | — |